51. In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations
- Author
-
Rahman Md Moshikur, Muhammad Moniruzzaman, Masahiro Goto, Md. Raihan Chowdhury, Rie Wakabayashi, Noriho Kamiya, and Yoshiro Tahara
- Subjects
Glycerol ,endocrine system ,Skin Neoplasms ,Paclitaxel ,Biocompatibility ,Ionic Liquids ,Pharmaceutical Science ,02 engineering and technology ,Pharmacology ,030226 pharmacology & pharmacy ,Drug Hypersensitivity ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Delivery Systems ,0302 clinical medicine ,Pharmacokinetics ,In vivo ,Cell Line, Tumor ,Animals ,Distribution (pharmacology) ,Solubility ,Melanoma ,021001 nanoscience & nanotechnology ,Antineoplastic Agents, Phytogenic ,In vitro ,Mice, Inbred C57BL ,chemistry ,Drug delivery ,Administration, Intravenous ,Female ,0210 nano-technology - Abstract
In order to prevent common hypersensitivity reactions to paclitaxel injections (Taxol), we previously reported an ionic liquid-mediated paclitaxel (IL-PTX) formulation with small particle size and narrow size distribution. The preliminary work showed high PTX solubility in the IL, and the formulation demonstrated similar antitumor activity to Taxol, while inducing a smaller hypersensitivity effect in in vitro cell experiments. In this study, the stability of the IL-PTX formulation was monitored by quantitative HPLC analysis, which showed that IL-PTX was more stable at 4 °C than at room temperature. The in vivo study showed that the IL-PTX formulation could be used in a therapeutic application as a biocompatible component of a drug delivery system. To assess the in-vivo biocompatibility, IL or IL-mediated formulations were administered intravenously by maintaining physiological buffered conditions (neutral pH and isotonic salt concentration). From in vivo pharmacokinetics data, the IL-PTX formulation was found to have a similar systemic circulation time and slower elimination rate compared to cremophor EL mediated paclitaxel (CrEL-PTX). Furthermore, in vivo antitumor and hypersensitivity experiments in C57BL/6 mice revealed that IL-PTX had similar antitumor activity to CrEL-PTX, but a significantly smaller hypersensitivity effect compared with CrEL-PTX. Therefore, the IL-mediated formulation has potential to be an effective and safe drug delivery system for PTX.
- Published
- 2019
- Full Text
- View/download PDF